Clinical Phenotype and Genetic Analysis of Twins With Congenital Coagulation Factor V Deficiency

Yanhui Wei, MMed,* Yuzhuo He, MMed† and Xuejun Guo, MD†

Objective: The aim was to investigate the clinical characteristics and molecular pathogenic mechanism of twins with congenital factor V (FV) deficiency.

Methods: We comprehensively analyzed the clinical manifestations and laboratory test results of a set of twins and their parents and performed point mutation analysis with direct high-throughput exon sequencing.

Results: The prothrombin time and activated partial thromboplastin time were prolonged for both probands, and the FV activity levels were 13.0% and 9.8%. Next-generation sequencing showed that the affected individuals harbored a paternal c.5113A>C (p.S1705R) and a maternal c.4949C>T (p.A1650V) heterozygous variants in the FV gene, which conformed to an autosomal recessive inheritance pattern. This is the first report of these point mutations. The older boy also had a congenital patent foramen ovale.

Conclusion: In this set of twins, missense mutations of the FV gene were related to congenital FV deficiency but unrelated to the patent foramen ovale observed in the older boy.

Key Words: coagulation factor V deficiency, FV gene, gene mutation

(J Pediatr Hematol Oncol 2022;44:e482–e486)

Factor V deficiency (FVD) (OMIM 227400), an autosomal recessive disorder, is a rare hereditary coagulation disorder related to factor V (FV) mutations with a prevalence of one per one million individuals.1–3 The FV gene is located on human chromosome 1q23 and contains 25 exons and 24 introns, and its messenger RNA (mRNA) has 6914 base pairs that encode FV, an inactive protein of 2224 amino acids (OMIM 612309). FV, a high-molecular-weight glycoprotein (330 kDa), consists of 6 domains (A1, A2, B, A3, C1, and C2) and is involved in coagulation by regulating the formation of thrombin.4,6 Clinical manifestations of FVD vary among patients, ranging from mild epistaxis, bruises, and increased menstrual flow to severe spontaneous bleeding of the digestive tract, skin, and mucous membranes, as well as bleeding problems after injury or surgery.5 To date, few cases of FV genetic variation have been reported domestically or abroad. Mutations are classified according to the American College of Medical Genetics and Genomics (ACMG)/Association for Molecular Pathology (AMP) guidelines with reference to the Human Gene Mutation Database (HGMD) and database of single nucleotide polymorphisms (dbSNP) public databases,7 and 159 mutation sites have been found to be related to FVD as of this manuscript’s submission. In this study, we used targeted capture and high-throughput next-generation sequencing (NGS) to analyze the genetic variations in a set of twins and their parents with FVD to provide a basis for genetic counseling of the family.

CASE DESCRIPTION

Patients

Ten-year-old male twins visited the Department of Hematology of our hospital because of recurrent, multiple, scattered bruises on the skin of the limbs and intermittent nasal bleeding. The maximum range of ecchymosis was 94×43 mm, and the smallest was 23×16 mm. The parents were unaffected. Laboratory tests showed that the activated partial thromboplastin time (APTT) and prothrombin time (PT) were significantly prolonged; fibrinogen, thrombin time, and the international normalized ratio were normal; and the activities of factors V, VII, and XII were low. A physical examination showed that the twins were conscious, without additional signs of bleeding, such as vomiting blood or blood in stools. All other tests were normal. Color ultrasound B examination of the heart, liver, gallbladder, spleen, pancreas, and kidneys showed congenital patent foramen ovale in the older boy but no abnormal findings in the younger boy. The parents of the probands were not in a consanguineous marriage and had normal laboratory test results and no history of bleeding or thrombosis.

Methods

Sample Collection

After obtaining informed consent and signatures from the probands’ guardian and their parents, 2 peripheral blood samples (3 to 5 mL for each sample) were collected in ethylenediaminetetraacetic acid-treated tubes from each proband and parent; one sample was centrifuged to obtain blood samples (3 to 5 mL for each sample) were collected in ethylenediaminetetraacetic acid-treated tubes from each proband and parent; one sample was centrifuged to collect the supernatant for routine coagulation tests, and the other sample was used to extract DNA for polymerase chain reaction (PCR) analysis.

Genetic Analysis

A blood sample (3 to 5 mL) from each proband and their parents was sent to Guangzhou KingMed Diagnostics (Guangzhou, China) for targeted genetic testing for hematology with high-throughput sequencing (Illumina, USA), with coverage of 99% or higher for targeted sequences. Candidate gene variation sites were screened and
TABLE 1. Laboratory Tests in the Probands and Pedigree Members With Hereditary FVD

|                  | APTT (s) | PT (s) | V:C (%) | VIII:C (%) | XII:C (%) | vWF:Ag (%) |
|------------------|---------|--------|---------|------------|-----------|------------|
| Older boy        | 55.40   | 16.00  | 9.80    | 35.60      | 46.00     | 89.20      |
| Younger boy      | 49.60   | 15.30  | 13.00   | 38.20      | 47.60     | 92.90      |
| Mother           | 31.50   | 12.30  | 63.20   | 53.50      | 80.20     | 108.20     |
| Father           | 32.20   | 11.70  | 64.60   | 63.20      | 91.30     | 103.20     |
| Reference range  | 27-45   | 11-14  | 62-139  | 50-150     | 50-150    | 94.10 ± 32.50 |

APTT indicates activated partial thromboplastin time; FVD, factor V deficiency; PT, prothrombin time.

Changes in the Spatial Structure of the Protein

On the basis of the crystal structure model from PubMed (pdb: 1FV4), the three-dimensional structure of the FV protein with c.4949C>T (p.A1650V) and c.5113A>C (p.S1705R) genetic variants was predicted with SWISS-MODEL, a protein structure homology modeling server.

RESULTS

Laboratory Tests and Clinical Manifestations

Laboratory tests for routine blood coagulation and coagulation factor activities of all pedigree members showed that the PT and APTT were prolonged in the twins (16.00 and 55.40 s for the older twin; 15.30 and 49.60 s for the younger twin) and were normal in both parents. For the set of twins, the relative activity of FV (V:C) was decreased to 9.8% and 13.00%; for factor VIII, (VIII:C) activity was decreased to 35.60% and 38.20%; and for factor XII, (XII:C) activity was decreased to 46.00% and 47.60%. All other coagulation factors were normal. The parents had normal results (Table 1).

Sanger Sequencing

Sanger sequencing revealed that the twins harbored a c.4949C>T (p.A1650V) missense mutation in FV exon 14 and a c.5113A>C (p.S1705R) missense mutation in FV exon 15, which is consistent with the NGS results (Fig. 1). Pedigree verification revealed maternal exon 14 mutation and paternal exon 15 mutations, indicating autosomal recessive inheritance. A review of several databases revealed that c.4949C>T (p. A1650V) was included only in the dbSNP database with "unknown" pathogenicity and had not been reported in any other database, such as HGMD, the exome variant server ESP-6500, and the 1000 Genomes Project; c.5113A>C (p.1705R) had not been reported in any of these databases.

Analysis of the Biological Characteristics of the Protein

Both twins harbored both mutation sites, 1 maternal and 1 paternal. The maternal mutation, c.5113A>C, alters FV residue 1750. We then used SWISS-MODEL to predict the structure of the FV variant S1705R. Figure 2 shows that residue 1750 was changed from serine (Ser) to arginine (Arg), with a significant impact on the conformation of surrounding amino acid residues mainly because of the increased volume of the Arg side chain. Moreover, Arg has a different charge and can form more hydrogen bonds and electrostatic interactions with surrounding residues. Figure 2 shows that the change from Ser1705 to Arg1705 enhances hydrogen bonding between Ser1626 and Arg1659, with certain effects on the conformation of surrounding residues. However, the maternal mutation, c.4949C>T, alters FV residue 1650. Figure 3 shows that residue 1650 was changed from alanine (Ala) to valine (Val), with minimal effects on the conformation of surrounding amino acid residues. However, the larger side chain allows Val1650 to form hydrophobic interactions with more surrounding amino acid residues. The combination of the 2 mutations further aggravated the change in protein conformation.

DISCUSSION

FV was discovered by Paul Oweren in 1943. FV is encoded by the FV gene, located on chromosome 1q23, and consists of 25 exons and 24 introns. The FV gene is related to the multicopper oxidase family and is highly homologous to factor VIII and ceruloplasmin. FV is primarily produced in the liver as a proprotein with 2240 amino acids, which is then preprocessed and secreted as a single-stranded glycoprotein with 2196 amino acids (molecular weight ≈ 33,000). FV has domains A1, A2, B, A3, C1, and C2 and is circulated in the blood as a large single-stranded cofactor. In FV domain B, proteolysis at Arg709, Arg1018, and Arg1545 simultaneously removes the inhibitory B domain and forms the heterodimer cofactor Va. Factor Va consists of a heavy chain containing domain A1-A2 (molecular weight ≈ 33,000).
weight \( \approx 105,000 \) noncovalently bound to a light chain containing domain A3-C1-C2 (molecular weight \( \approx 74,000 \)) through calcium ions.\(^{12}\) The amino acid sequence of the light chain is partially homologous to the carboxyl terminal sequence of human factor VIII. The factor Va level is \( \sim 20 \text{ nM}. \)\(^{13-15}\) Factor Va acts as a cofactor during coagulation to substantially improve the catalytic efficiency of large enzyme complexes, thereby playing an important role in the rapid formation of thrombin. Congenital FVD is usually related to FV gene defects that lead to loss of function of FV. The condition is characterized by autosomal recessive inheritance and was first discovered in 1954 by Kingsley\(^{16}\) in a consanguineous pedigree. Clinically relevant nonsense, frameshift, missense, and splice site mutations of the FV gene have been described. The serum FV level is usually less than 10% to 20% in affected individuals with homozygous or compound heterozygous mutations and less than 50% in heterozygous individuals with mild or moderate FVD.\(^{17}\) FV activity is also abnormal. Researchers are still debating the relationship between FV activity and the severity of bleeding.\(^{4}\) Studies have shown that FV activity > 15% is generally observed in asymptomatic individuals or individuals with mild bleeding,\(^{17}\) while FV activity <10% is associated with varying clinical manifestations and varying severity of bleeding.\(^{18}\) Kingsley\(^{16}\) examined 2 pedigrees and found that heterozygous individuals were asymptomatic when FV activity was 24% to 68%. Other studies note that the severity of bleeding varies in patients with the same mutation or FV activity, including those with the same genotype and low FV activity (<1%).\(^{19}\) In addition, studies show that in most cases, FVD manifests as skin and mucous membrane bleeding rather than joint bleeding, as observed

**FIGURE 2.** Interaction between residue 1705 and surrounding residues in wild-type FV (A and B) and the S1705R variant (C and D).
in hemophilia patients. FVD can occur in individuals of any race, with a slightly higher prevalence in Middle Eastern Jews and non-Jewish Iranians, especially those from consanguineous marriages.

In summary, a set of twins had FVD with low activity levels of factors V, VIII, and XII, and genetic analysis revealed FV mutations. The current research suggests that hereditary FVD is generally caused by FV gene defects, which is in line with our research results. If a combined deficiency of FV and factor VIII is present, the condition could be caused by a disordered mutation of the endoplasmic reticulum-Golgi intermediate compartment gene ERGIC-53, which is also known as LMAN1. However, the condition may be caused by a mutation in the MCFD2 gene, a cofactor of the LMAN1 protein. The NGS results of the patients did not reveal the mutation site. If factor VIII deficiency is observed, the mutation site could be the long arm of the X chromosome (Xq-28) and inherited from the sex chromosome. In addition to the mutation site not matching these sites, the genetic characteristics described in this study did not match the mutant characteristics. Therefore, the possibility that the children had a combined FV and factor VIII deficiency and hemophilia A was excluded. NGS technology is currently commonly used for DNA sequence detection, but this technique may not provide direct evidence that can be used to diagnose the disease type. The reasons that FVD was considered were that, first, based on the activity of coagulation factors (FV was significantly decreased, while factor VIII was decreased to a lesser degree) and the patient’s 4 coagulation results, the PT and APTT were both prolonged, which is often observed with severe deficiency of factors II, V, or X or combined deficiency of factors V and VIII. The other reasons included the genetic characteristics of the patient’s family and finally the

FIGURE 3. Interaction between residue 1650 and surrounding residues in wild-type FV (A and B) and the A1650V variant (C and D).
patients’ second-generation sequencing results. We analyzed the reasons for the reduction in factor VIII activity. Because FV and factor VIII are both coagulation cofactors, it cannot be ruled out that the drastic reduction in FV affected the content of factor VIII in the coagulation cascade. The twins suffered from the disease at the same time, and both had the content of factor VIII in the coagulation cascade. The twins were ruled out that the drastic reduction in FV affected the reasons for the reduction in factor VIII activity. Because the maternal variation, c.4949C>T, is included in the dBSNP database, but the pathogenicity is unknown, especially since the mother is a carrier with a normal phenotype. Animal studies are needed to further investigate this mutation, especially given its low probability of being pathogenic. Similarly, the paternal variation, c.5113A>C, has not been reported in any database, but the father has a normal phenotype.

ACKNOWLEDGMENTS

The authors would like to thank the technical team of Dr Xiaowu Zhao from Zhengzhou KingMed Diagnostics Company for their help and technical support.

REFERENCES

1. Lippi G, Favaloro EJ, Montagnana M, et al. Inherited and acquired factor V deficiency. Blood Coagul Fibrin. 2011;22:160–166.
2. Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood. 2004;104:1243–1252.
3. Girolami A, Marco LD, Zanon RDB, et al. Rarer quantitative and qualitative abnormalities of coagulation. Clin Haematology. 1985;14:385–411.
4. Huang JN, Koerper MA. Factor V deficiency: a concise review. Haemophilia. 2008;14:1164–1169.
5. Asselta R, Tenchini ML, Duga S. Inherited defects of coagulation factor V: the hemorrhagic side. J Thromb Haemost. 2006;4:26–34.
6. Kane WH, Ichinose A, Hagen FS, et al. Cloning of cDNAs coding for the heavy chain region and connecting region of human factor V: a blood coagulation factor with four types of internal repeats. Biochemistry. 1987;26:6508–6514.
7. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–424.
8. Owren PA. Parahaemophilia: haemorrhagic diathesis due to absence of a previously unknown clotting factor. Lancet. 1947;249:446–448.
9. Wang A, Liu X, Wu J, et al. Combined FV and FVIII deficiency (F5F8D) in a Chinese family with a novel missense mutation in MCFD2 gene. Haemophilia. 2014;20: e436–e438.
10. Nuzzo F, Bulato C, Nielsen BI, et al. Characterization of an apparently synonymous F5 mutation causing aberrant splicing and factor V deficiency. Haemophilia. 2015;21:241–248.
11. Camire RM, Bos MHA. The molecular basis of factor V and VIII procofactor activation. J Thromb Haemost. 2009;7:1951–1961.
12. Mann KG, Nesheim ME, Church WR, et al. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood. 1990;76:1–16.
13. Wilson DB, Salem HH, Mruk JS, et al. Biosynthesis of coagulation Factor V by a human hepatocellular carcinoma cell line. J Clin Invest. 1984;73:654–658.
14. Mazzorana M, Baffet G, Kneip B, et al. Expression of coagulation factor V gene by normal adult human hepatocytes in primary culture. Br J Haematol. 1991;78:229–235.
15. Tracy PB, Eide LL, Bowie EJ, et al. Radioimmunoassay of factor V in human plasma and platelets. Blood. 1982;60:59–63.
16. Kingsley CS. Familial factor V deficiency: the pattern of heredity. Q J Med. 1954;23:323–329.
17. Asselta R, Peyvandi F. Factor V deficiency. Semin Thromb Hemost. 2009;35:382–389.
18. Thalji N, Camire R. Parahemophilia: new insights into factor V deficiency. Semin Thromb Hemost. 2013;39:607–612.
19. Kalafatis M. Coagulation factor V: a plethora of anticoagulant molecules. Curr Opin Hematol. 2005;12:141–148.